ReproCELL

21 articles about ReproCELL

• NeuCyte and REPROCELL enter distribution agreement in North America and Europe

  9/25/2019

  This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements.

• ROSLINCT and REPROCELL Awarded £1.2 Million from Innovate UK for Clinical-Grade Stem Cell Production

  10/10/2018

  Funding will be used to improve efficiency of induced pluripotent stem cell production

• Q Therapeutics Announces Research Collaboration With REPROCELL

  12/13/2017

  Q Therapeutics has patented a process to manufacture glial-restricted progenitor (GRP) cells from any tissue source.

• REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

  11/8/2017

  Science Exchange announced today that ReproCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.

• Nicola Sturgeon, First Minister Of Scotland, Opens ReproCELL European Headquarters In Glasgow

  8/10/2017

• ReproCELL And Fox Chase Cancer Center Partner To Open Multi-Site Biosample Repository In India

  5/25/2017

• ReproCELL And Fox Chase Cancer Center Form Strategic Alliance To Accelerate Biomarker And Genetic Discovery

  4/13/2017

• ReproCELL Establishes European Headquarters Through Merger Of Biopta And Reinnervate Limited

  7/5/2016

• ReproCELL Announced: A Joint Development With The National Cancer Center

  12/28/2015

• ReproCELL Announced: Regarding The Synergistic Effects Of Our Complete Subsidiary Acquisition Of Biopta

  11/30/2015

• ReproCELL Acquires Biopta To Expand Its Drug Discovery Services

  11/25/2015

• ReproCELLl: Joint Press Announcement With Institute For Frontier Medical Sciences, Kyoto University

  8/26/2015

• ReproCELL Announced: Sales Commencement Of "Reproneuro MQ Medium", A Cell Culture Kit Which Enables The Creation Of High-Functioning Nerve Cells Derived From Human iPS Cells

  7/22/2015

• Stemgent, A ReproCELL Group Company Launches A New High Performance Self-replicative RNA Reprogramming Kit

  6/30/2015

• ReproCELL Launches New Culture Medium For High Quality Human Naïve iPS Cells, "ReproNaïve"

  6/22/2015

• Cancer Genetics, Inc. Selected To Power Next-Generation Sequencing Services For ReproCELL, A Global Regenerative Medicine Market Leader, In A Multi-Year Agreement

  5/26/2015

• ReproCELL Launches Cell Innovation Partners, L.P. With Shinsei Bank, Limited

  9/29/2014

• ReproCELL Acquires The iPS Cell Business Unit Of Stemgent, Inc.

  9/9/2014

• Stem Cell Company ReproCELL (Japan) Acquires 3D Cell Culture Company Reinnervate Limited (UK) And Human Tissue Supplier Bioserve (USA)

  8/5/2014

• ReproCELL Announces Approval for Listing on the Osaka Stock Exchange JASDAQ Market Growth

  5/29/2013